Sign up
Hero

What is tenosynovial
giant cell tumor (TGCT)?

What is tenosynovial
giant cell tumor (TGCT)?

TGCT is also formerly known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS)

TGCT is a chronic disease where tumors form in the body's joints causing pain, swelling, and loss of range of motion in the affected joint. TGCT may cause permanent damage to the joint.*

*In a study of patients with diffuse TGCT, 8 out of 45 patients (18%) who did not have osteoarthritis at baseline developed signs of joint damage.

People

11-50 casesper million people annually

A data point

33 years of agethe median age of diagnosis

TGCT is also formerly known as pigmented villonodular synovitis (PVNS) or giant cell tumor of the tendon sheath (GCT-TS)

TGCT is a chronic disease where non-malignant tumors form in the body's joints causing pain, swelling, and loss of range of motion in the affected joint. TGCT may cause permanent damage to the joint.*

*In a study of patients with diffuse TGCT, 8 out of 45 patients (18%) who did not have osteoarthritis at baseline developed signs of joint damage.

A mother and her toddler playing with toys

There are two types of TGCT:

Localized/nodular TGCT is more common and tends to be smaller, well‑defined tumors inside or outside of the joint.

Diffuse TGCT is less common and tends to be larger tumors with ill‑defined boundaries.

For use in adult patients only.

Debbie, a  ROMVIMZA® (vimseltinib) patient with TGCT (tenosynovial giant cell tumor)
Debbie, a  ROMVIMZA® (vimseltinib) patient with TGCT (tenosynovial giant cell tumor)

Because TGCT is benign, people automatically think it can be fixed. The truth is, it can still be serious and have a major impact on day-to-day life.

Debbie,
a real patient on ROMVIMZA
Two rotating arrows

High recurrence can potentially create lifelong burdens:

  • Up to 72% recurrence rate for diffuse TGCT
  • Up to 15% recurrence rate for localized/nodular TGCT
A person walking

TGCT can significantly impact daily living

According to an observational study of 497 adults with TGCT, conducted by TGCT Support:

  • 92% of patients reported pain, with pain impacting many areas of daily life, from household chores and social activities (77.9%) to family life (75.9%)
  • 85% of patients reported limited range of motion
  • 23% of patients reported that they changed occupations or retired early due to their TGCT, with higher rates in patients who had more than 2 surgeries
  • Impact on household activities, including:
    • Daily chores, like vacuuming or yard work (73.9%)
    • Going for a walk that lasts at least 15 minutes (63.3%)
    • Running errands and shopping (62.0%)
    • Going up and down the steps at a normal pace (77.1%)
Art, a  ROMVIMZA® (vimseltinib) patient with TGCT (tenosynovial giant cell tumor)

Treating TGCT: surgery or prescription medicines?

While TGCT is often treated with surgery, surgery isn't right for everyone, and not all tumors can be removed.

A speech bubble and a doctor

Want to learn more about TGCT?

TGCT Support has information, statistics, support, and resources to help you better understand the condition.

Visit TGCT Support

TGCT Support is an independent organization that is not affiliated with Deciphera. Deciphera is not responsible for the content on TGCT Support’s website or any services or materials it may provide.

Deciphera Pharmaceuticals logo
Contact Usdeciphera.comTerms of UsePrivacy Policy

© 2026 Deciphera Pharmaceuticals, LLC. The following are registered trademarks of Deciphera Pharmaceuticals, LLC.: Deciphera, Deciphera logo, ROMVIMZA, and ROMVIMZA logo. The following are service marks of Deciphera Pharmaceuticals, LLC.: Deciphera AccessPoint and Deciphera AccessPoint logo. All rights reserved. All logos and trademarks are the sole property of their respective owners.
DCPH-P02854v2 08/26